Scotiabank Maintains Outperform for Merck & Co., Inc. (MRK) Feb 2026
On February 3, 2026 Scotiabank maintained an Outperform view on Merck & Co., Inc. (MRK) and raised its price target to $136 from $120, updating the MRK analyst rating. The action keeps a positive tilt while stopping short of an upgrade to Buy. Scotiabank’s move signals confidence in Merck’s drug pipeline and near-term earnings stability.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
